{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fruquintinib+%28HMPL-013%29", "query": { "intervention": "Fruquintinib (HMPL-013)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 20, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fruquintinib+%28HMPL-013%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T02:13:07.354Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06992258", "title": "A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Fruquintinib+ Lonsurf (trifluridine and tipiracil)", "type": "DRUG" }, { "name": "Fruquintinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Criterium, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-10-27", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-28T02:13:07.354Z", "location_count": 13, "location_summary": "New Haven, Connecticut • Miami Beach, Florida • Orlando, Florida + 10 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06992258" }, { "nct_id": "NCT05867420", "title": "A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "ASKG915", "type": "BIOLOGICAL" }, { "name": "Paclitaxel + Bevacizumab", "type": "DRUG" }, { "name": "Fruquintinib", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AskGene Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 594, "start_date": "2023-08-02", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-01-27", "last_synced_at": "2026-09-28T02:13:07.354Z", "location_count": 2, "location_summary": "New York, New York • Pittsburgh, Pennsylvania", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867420" }, { "nct_id": "NCT05405595", "title": "ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced/Metastatic Solid Tumors" ], "interventions": [ { "name": "ADG126", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" }, { "name": "Standard of Care (Trifluridine/Tipiracil-Bevacizumab)", "type": "DRUG" }, { "name": "Standard of care (Fruquintinib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adagene Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2022-06-15", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-09-28T02:13:07.354Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Duarte, California • Irvine, California + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05405595" }, { "nct_id": "NCT07011576", "title": "A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer", "Rectal Cancer", "Colorectal Cancer", "Colorectal Cancer (CRC)" ], "interventions": [ { "name": "fruquintinib", "type": "DRUG" }, { "name": "FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-09-29", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-09-28T02:13:07.354Z", "location_count": 14, "location_summary": "Denver, Colorado • Arlington Heights, Illinois • Columbia, Maryland + 11 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Arlington Heights", "state": "Illinois" }, { "city": "Columbia", "state": "Maryland" }, { "city": "Maple Grove", "state": "Minnesota" }, { "city": "Columbia", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07011576" }, { "nct_id": "NCT04322539", "title": "A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Colorectal Cancer", "Metastatic Colon Cancer" ], "interventions": [ { "name": "Fruquintinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchison Medipharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 691, "start_date": "2020-08-12", "completion_date": "2024-04-24", "has_results": true, "last_update_posted_date": "2025-04-04", "last_synced_at": "2026-09-28T02:13:07.354Z", "location_count": 45, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 39 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04322539" }, { "nct_id": "NCT07130903", "title": "Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Adenocarcinoma" ], "interventions": [ { "name": "Fruquintinib", "type": "DRUG" }, { "name": "TheraBionic P1", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 102, "start_date": "2025-09-10", "completion_date": "2030-04-17", "has_results": false, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-09-28T02:13:07.354Z", "location_count": 9, "location_summary": "Bay City, Michigan • Clarkston, Michigan • Detroit, Michigan + 6 more", "locations": [ { "city": "Bay City", "state": "Michigan" }, { "city": "Clarkston", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Flint", "state": "Michigan" }, { "city": "Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07130903" }, { "nct_id": "NCT04557397", "title": "Fruquintinib CYP3A Inhibitor and Inducer Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Drug Interaction" ], "interventions": [ { "name": "Fruquintinib", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchison Medipharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 28, "start_date": "2020-09-02", "completion_date": "2020-10-18", "has_results": false, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-09-28T02:13:07.354Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04557397" }, { "nct_id": "NCT04645940", "title": "Fruquintinib Food Effect and Proton Pump Inhibitor Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interaction", "Food-drug Interaction" ], "interventions": [ { "name": "fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole", "type": "DRUG" }, { "name": "fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchison Medipharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 14, "start_date": "2020-09-24", "completion_date": "2020-11-18", "has_results": false, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-09-28T02:13:07.354Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04645940" }, { "nct_id": "NCT03251378", "title": "A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Colon Cancer", "Metastatic Breast Cancer", "Triple Negative Breast Cancer", "HER2-negative Breast Cancer", "Hormone Receptor Positive Breast Carcinoma", "Rectal Cancer" ], "interventions": [ { "name": "Fruquintinib (HMPL-013)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchison Medipharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2017-12-11", "completion_date": "2023-03-30", "has_results": true, "last_update_posted_date": "2024-09-25", "last_synced_at": "2026-09-28T02:13:07.354Z", "location_count": 9, "location_summary": "Phoenix, Arizona • San Marcos, California • Santa Rosa, California + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Marcos", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Port Saint Lucie", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03251378" }, { "nct_id": "NCT05565417", "title": "Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma", "Triple Negative Breast Cancer", "Cutaneous Squamous Cell Carcinoma", "Hormone Receptor Positive Breast Carcinoma", "Small Bowel Cancer", "Esophageal Cancer", "Colorectal Cancer", "Diffuse Large B Cell Lymphoma", "Hodgkin Lymphoma", "Burkitt Lymphoma", "Follicular Lymphoma" ], "interventions": [ { "name": "IMT-009", "type": "DRUG" }, { "name": "Fruquintinib", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Immunitas Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2022-11-28", "completion_date": "2026-01", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-09-28T02:13:07.354Z", "location_count": 9, "location_summary": "Tucson, Arizona • Denver, Colorado • Orlando, Florida + 6 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT05565417" } ] }